Investment analysts at StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Down 0.4 %
Shares of EVOK opened at $4.82 on Monday. Evoke Pharma has a 52-week low of $3.54 and a 52-week high of $12.32. The company has a market capitalization of $7.16 million, a PE ratio of -0.44 and a beta of 0.16. The stock has a fifty day simple moving average of $4.73 and a two-hundred day simple moving average of $4.81.
Institutional Trading of Evoke Pharma
An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. bought a new position in Evoke Pharma, Inc. (NASDAQ:EVOK – Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma as of its most recent SEC filing.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Further Reading
- Five stocks we like better than Evoke Pharma
- How to Read Stock Charts for Beginners
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- Insider Trading – What You Need to Know
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
